Dan Turner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dan Turner has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Adrian Streinu-Cercel
Department of Infectious Diseases I, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania
1 shared publication - José Ramón Arribas
Department of Internal Medicine, HIV Unit, La Paz University Hospital , Madrid
1 shared publication - Linos Vandekerckhove
HIV Cure Research Center, Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium
1 shared publication - Manuela Doroana
Serviço de Doenças Infecciosas, Hospital de Santa Maria, Av Prof Egas Moniz, Lisbon, 1649-035, Portugal
1 shared publication On Behalf Of The Panel Members
1 shared publication
Latest Publications
- Open Access
- 1 January 2013
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 10 (1) , 1-9
Boosted protease inhibitor monotherapy in HIV-infected adults: outputs from a pan-European expert panel meeting
While the introduction of combination highly active antiretroviral therapy (HAART) regimens represents an important advance in the management of human immunodeficiency virus (HIV)-infected patients, tolerability can be an issue and the use of several different agents may produce problems. The switch of combination HAART to ritonavir-boosted protease inhibitor (PI) monotherapy may offer the opportunity to maintain antiviral efficacy while reducing treatment complexity and the risks of toxicity. Current European AIDS Clinical Society (EACS) guidelines recognise ritonavir-boosted PI monotherapy with twice-daily lopinavir/ritonavir or once-daily darunavir/ritonavir as a possible option in patients who have intolerance to nucleoside reverse transcriptase inhibitors, or for treatment simplification. Clinical trials data for PI boosted monotherapy are encouraging, showing substantial efficacy in the majority of patients; however, further data are required before this approach can be recommended as a routine treatment. Available data indicate that the most suitable candidates for the use of boosted PI monotherapy are long-term virologically suppressed patients who have demonstrated good adherence to antiretroviral therapy, who do not have chronic hepatitis B, have no history of treatment failure on PIs and are able to tolerate low-dose ritonavir.
- 1 January 2013
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 10 (1) , 1-9
Open AccessBoosted protease inhibitor monotherapy in HIV-infected adults: outputs from a pan-European expert panel meeting
While the introduction of combination highly active antiretroviral therapy (HAART) regimens represents an important advance in the management of human immunodeficiency virus (HIV)-infected patients, tolerability can be an issue and the use of several different agents may produce problems. The switch of combination HAART to ritonavir-boosted protease inhibitor (PI) monotherapy may offer the opportunity to maintain antiviral efficacy while reducing treatment complexity and the risks of toxicity. Current European AIDS Clinical Society (EACS) guidelines recognise ritonavir-boosted PI monotherapy with twice-daily lopinavir/ritonavir or once-daily darunavir/ritonavir as a possible option in patients who have intolerance to nucleoside reverse transcriptase inhibitors, or for treatment simplification. Clinical trials data for PI boosted monotherapy are encouraging, showing substantial efficacy in the majority of patients; however, further data are required before this approach can be recommended as a routine treatment. Available data indicate that the most suitable candidates for the use of boosted PI monotherapy are long-term virologically suppressed patients who have demonstrated good adherence to antiretroviral therapy, who do not have chronic hepatitis B, have no history of treatment failure on PIs and are able to tolerate low-dose ritonavir.